AMERICAN CHEMICAL SOCIETYHEROES OF CHEMISTRY

The ACS Heroes of Chemistry program honors chemical scientists whose work in various fields of chemistry and chemical engineering has led to the successful innovation and development of commercial products based on chemistry. These industrial scientists are celebrated for their inventive contributions to their companies, the chemical enterprise, and humankind.

Each year, Heroes of Chemistry are nominated by the companies with whom they work to recognize the talent and creativity of their scientists in specific industry segments of the chemical enterprise. Our previous Heroes of Chemistry have excelled in their innovative work at prominent international corporations developing commercial products that demonstrate strong financial performance. The commercial success of their products in the marketplace is an important criterion for this honor, because we recognize that good business results follow good science.

This year’s program highlights the vital role industrial chemical scientists and their companies play in improving human health and well-being through new chemical innovations. The Heroes of Chemistry program presents an ideal opportunity to enhance the public image of our chemical, pharmaceutical, and allied industries at the national level.

We honor these scientists for their inquisitive, progressive minds. They have demonstrated their ability to commercialize cutting-edge scientific and technological advances for the benefit of society.

ACS salutes each company for creating an internal R&D environment that encourages scientific discovery and facilitates chemical advancement. The leaders of these corporations promote the creativity, risk taking, problem solving, teamwork, and collaborations that make the innovative work of our Heroes possible.

Nominations for the 2016 Heroes of Chemistry awards will be accepted starting in January 2016. Please visit www.acs.org/heroes or contact chemhero@acs.org for more information.

6:30 p.m. Reception

7:30 p.m. Welcoming RemarksThomas Connelly, Jr., Executive Director and Chief Executive Officer, American Chemical Society

7:45 p.m. Dinner

8:45 p.m. Awards CeremonyRemarks - Diane Grob Schmidt, President, American Chemical Society Video tributes and recognition of the 2015 ACS Heroes of Chemistry

Bristol-Myers Squibb Robert Knabb, Patrick Lam, Michael Orwat, Donald Pinto, Mimi Quan, Pancras Wong

Celgene Corporation George Muller, Roger Shen-Chu ChenThe Dow Chemical Company David Devore, Morris Edmondson, Pradeep Jain, George Knight,

Brian Kolthammer, Shih-Yaw Lai, Robert LaPointe, David Neithamer, Peter Nickias, Jasson Patton, Robert Rosen, James Stevens, Francis Timmers, Daniel VanderLende, David Wilson

Eastman Chemical Company Benjamin Barton, Emmett Crawford, Ted Germroth, Christopher Killian, Anthony Messina, David Porter

Gilead Sciences Benjamin Greatz, John Link, Erik Mogalian, Rowchanak Pakdaman, Bruce Ross, Bob Scott, Michael Sofia, Cheng Yong (Chris) Yang

Pfizer Douglas Ball, Todd Blumenkopf, William Brissette, Matthew Brown, Frank Busch, Paul Changelian, Robert Dugger, Eileen Elliott, Michael Fisher, Mark Flanagan, Sally Gut-Ruggeri, Elizabeth Kudlacz, Michael Munchhof, Chakrapani Subramanyam, Frank Urban, Rajappa Vaidyanathan

10:00 p.m. Closing Remarks

Program

Pancras Wong is Senior Research Fellow in Discovery at Bristol-Myers Squibb and conducts research in thrombosis and heart failure. He earned his B.A. in chemistry from the University of Oregon and Ph.D. in pharmacology from the University of Minnesota.

Robert Knabb is a Group Director in Cardiovascular Specialty Development at Bristol-Myers Squibb, and formerly co-chair of the Factor Xa inhibitor working group that discovered ELIQUIS® (apixaban). He obtained his B.S. in science from Pennsylvania State University, and Ph.D. in physiology from the University of Virginia.

Patrick Lam is the former Bristol-Myers Squibb director/chemistry project leader for the discovery of ELIQUIS® (apixaban). Since his retirement, he has been an adjunct professor at Drexel University College of Medicine. He received his B.S. from Ateneo de Manila University, Ph.D. from the University of Rochester and is co-discoverer of the Chan-Lam Coupling Reaction.

Michael Orwat is a Senior Research Scientist in Discovery Chemistry at Bristol-Myers Squibb. He obtained his B.S. degree in chemistry from the University of Pittsburgh and his M.S. degree in organic chemistry from the University of Rochester.

Donald Pinto is a Research Fellow at Bristol-Myers Squibb. He obtained his B.S. and M.S. degrees from the University of Bombay India, and his Ph.D. from the State University of New York at Buffalo, and post doctoral training at the Rensselaer Polytechnic Institute.

Mimi Quan is a Research Fellow at Bristol-Myers Squibb. She obtained her B.S and Ph.D. in organic chemistry from the University of California, Los Angeles, and attended Zhanjiang Medical College in China.

The American Chemical Society honors scientists from Bristol-Myers Squibb for the innovation and commerialization of EUQUIS®, (apixaban), an orally bioavailable small molecule Factor Xa (FXa) inhibitor that is administered as a safe and efficacious oral anticoagulant agent during the treatment of cardiovascular disease.

Roger Shen-Chu Chen was a Research Fellow with Celgene until he retired in December 2010. He received his B.S. from Cheng Kung University, Taiwan, his M.S from Cleveland State University, Ohio, his Ph.D. from the University of Texas at Austin, and his Post-Doctoral Research Associate at Cornell University.

The American Chemical Society honors scientists from Celgene Corporation who discovered and characterized POMALYST® (pomalidomide), an oral immunomodulatory agent used successfully to treat relapsed refractory multiple myeloma in cancer patients.

George Muller was an Outstanding Investigator with Celgene until his early retirement in mid-2011 and currently works as a consultant. He obtained a B.S. in chemistry from Colorado State University, Fort Collins, and a M.A. and Ph.D. in organic chemistry from the University of California, Santa Barbara.

David Devore developed the synthetic route used in the commercial production of the first generation INSITE™ catalyst and discovered and developed the second generation INSITE™ catalyst for Dow. He is currently a Dow Corporate Fellow. He earned a B.A. in chemistry from Augustana College and a Ph.D. in inorganic chemistry from Kansas State University.

Morris Edmondson designed the first commercial NORDEL™ IP EPDM product family based upon INSITE™ technology. He is currently Owner & CTO of E3Enterprise L.L.C., a product and process consulting company. He received a B.A. in chemistry from Texas State University as well as a M.A. and Ph.D. in organic chemistry from the University of Texas.

Pradeep Jain developed the first comprehensive kinetic reactor model for homogeneous polyolefins polymerization that was used to design and develop INSITE™ technology manufacturing process and unique polymers. He earned a Bachelor of Technology in chemical engineering from the Indian Institute of Technology, Varanasi (India) and a M.S.ChE from the University of New Mexico.

George Knight developed the INSITE™ technology polymers structure property relationships for applications development. Bill earned his B.A. from Abilene Christian College and a M.S. in science from Florida State University. At Dow, he was awarded the highest honor bestowed on a scientist, the HH Dow Medal in 1991, for his contributions to polymer science.

Brian Kolthammer developed the impurities scavenging technology for the INSITE™ catalyst. He is currently a Chemicals, Hydrocarbons and Performance Plastics R&D Corporate Fellow at Dow. Brian received his Ph.D. from the University of British Columbia.

Shih-Yaw Lai discovered the unique rheological characteristics of INSITE™ technology polymers, a key differentiation attribute. He received a B.S. in Chemical Engineering from Tatung Institute of Technology, his M.S. in chemical engineering from the University of Cincinnati, and his Ph.D. in macromolecular science and engineering from the University of Michigan.

Robert LaPointe’s studies in the continuous reactor process confirmed the long-chain-branched nature of the INSITE™ technology polymers. Bob received a B.S. in chemistry from St. John Fisher College, a Ph.D. in inorganic chemistry from Cornell University, and completed Post-Doctoral research at Washington State University and the University of Iowa.

The American Chemical Society honors scientists from The Dow Chemical Company for their innovation and commercialization of INSITE™ technology, a single-site, constrained-geometry metallocene catalysis platform that led to creation of novel polyethylene elastomers marketed under the brand names ENGAGE™, NORDEL™, and AFFINITY™.

James Stevens developed the first constrained geometry catalysts for olefin polymerization using the solution process. He has received the Dow “Inventor of the Year” award five times during his tenure at Dow. Jim received a B.A. in chemistry from the College of Wooster and a Ph.D. in inorganic chemistry from Ohio State University.

David Neithamer developed the first cationic constrained geometry catalyst systems and discovered novel co-catalyst technology at Dow. He received a B.S. in chemistry from Southwestern at Memphis (now Rhodes College), and his M.S. and Ph.D. in inorganic chemistry from Cornell University.

Peter Nickias was the first to recognize the unique influence of the constrained geometry catalyst structure on the polymer microstructure. He received a B.A. in chemistry from North Park College, a Ph.D. in inorganic chemistry from the University of Kentucky, and completed Post-Doctoral research at the University of Minnesota.

Jasson Patton performed a structure activity investigation of cyclopentadienyl and indenyl based Group IV constrained geometry catalysts for the copolymerization of ethylene/octene copolymers. These results directly led to the discovery of the current commercial catalyst. He received both a B.S. in chemistry and a Ph.D. in organic chemistry from the University of Florida.

Robert Rosen developed the co-catalyst technology and was instrumental in the scale-up of the catalyst for commercial implementation. He received a B.S. in chemistry from the University of Pennsylvania and a Ph.D. in inorganic chemistry from the University of California at Berkeley.

Francis Timmers effort and involvement led to the development of the INDEX™ family of ethylene styrene interpolymer. He received a B.A. in chemistry from St. Norbert College, a M.S. in inorganic chemistry from the University of Notre Dame, and a Ph.D. in inorganic chemistry from the University of North Carolina.

Daniel VanderLende worked as the Associate Research Director at Dow and led the scale-up and commercialization of the first catalyst specifically developed for use in the NORDEL™ IP EPDM system. He received a B.A. in chemistry from the College of Wooster and a Ph.D. in inorganic chemistry from the University of Florida.

David Wilson synthesized and developed the first constrained geometry catalyst which became the basis of INSITE™ Technology; he currently works for Dow Core R&D. He received both a B.S. and Ph.D. from the University of Utah. He also attended Institut für Anorganische Chemie der Universität Würzburg in West Germany for Post-Doctoral studies.

The American Chemical Society honors scientists from Eastman Chemical Company for the innovation and commercialization of Eastman TRITAN™Copolyesters, a new family of engineering plastics that are clear, tough, chemical-resistant, and free ofBisphenol A (BPA).

Benjamin Barton is a Senior Research Associate and Technology Manager for the Specialty Plastics Business at Eastman Chemical Company. He earned his B.S. in chemical engineering from the University of Kentucky and his M.S. and Ph.D. degrees in chemical engineering from the University of Illinois at Urbana-Champaign.

Emmett Crawford is currently a Research Fellow at Eastman Chemical Company and the lead inventor of TRITAN™ copolyesters. He earned his B.S. in chemical engineering from North Carolina State University, and his Ph.D. in polymer science and engineering from the University of Massachusetts at Amherst.

Ted Germroth is a Senior Fellow working in Specialty Products Technology at Eastman Chemical Company. He earned his B.S. in chemistry from the College of William and Mary in Virginia and M.S. and Ph. D. in synthetic organic chemistry from the University of California at Berkeley.

Chris Killian is Vice President, Specialty Products Technology for Eastman Chemical Company. He holds a Ph.D. in organic chemistry from the University of North Carolina-Chapel Hill. Killian joined Eastman in 1996 and during his career at Eastman, he has held various leadership positions in both technology and the business.

Anthony Messina is currently a Senior Development Associate with 33 years of service at Eastman Chemical Company. He earned his B.S., M.S., and Ph.D. in chemical engineering from the University of Missouri – Rolla. Prior to Eastman, he worked for four years as an Assistant Professor of Chemical Engineering at Texas A&M University.

David Porter is currently Technology Manager and Platform Leader for the AFP Polyester Coatings Platform at Eastman. Prior to this, David was Eastman’s Global Business Manager for the Displays and Optical Films business. He earned both Ph.D. and bachelor’s degrees in chemistry from Virginia Tech.

Benjamin Graetz is a Senior Scientist II in the Process Chemistry Department at Gilead Sciences. He earned a B.S. in chemistry with honors from Ohio State University and his Ph.D. in organic chemistry from the University of California, Irvine.

Erik Mogalian joined Gilead Sciences as a Research Scientist, Formulation and Process Development, and is currently a Senior Clinical Pharmacologist. He earned his Pharm.D. and Ph.D. in pharmaceutical sciences from the University of Arizona.

John Link is Senior Director, Medicinal Chemistry at Gilead Sciences. He earned his B.A. in chemistry at the University of Minnesota and a Ph.D. in organic chemistry in the laboratory of Professor E.J. Corey at Harvard University.

Rowchanak Pakdaman is a Senior Scientist II in the Formulation and Process Department of Gilead Sciences. She was a Postdoctoral fellow in the Chemistry Department of the University of New Hampshire and obtained her Ph.D. from the Université Paris Diderot - Paris 7.

The American Chemical Society honors scientists from Gilead Sciences for the innovation and commercialization of HARVONl®, the first single-tablet regimen, for the treatment of Hepatitis C virus. HARVONl® is a combination drug containing Sofosbuvir and Ledipasvir.

Cheng Yong (Chris) Yang is Director of Drug Metabolism at Gilead Sciences. He earned his B.Sc. in biochemistry from Sichuan University, his M.Sc. in biochemistry from Memorial University of Newfoundland and his Ph.D. in medicinal chemistry and molecular pharmacology from Purdue University.

Bruce Ross is Director of Process Research at Gilead Sciences. He received his B.S. in medicinal chemistry from the University of Michigan and Ph.D. in medicinal chemistry from the University of Kansas.

Michael Sofia is Chief Scientific Officer at Tekmira/OnCore Inc. He earned a B.A. in chemistry from Cornell University and his Ph.D. in organic chemistry from the University of Illinois, Urbana-Champaign.

Bob Scott is Senior Director of Process Chemistry at Gilead Sciences. He earned his B.S. in chemistry from the University of California, Davis and his Ph.D. in chemistry from the University of California, Berkeley.

Matthew Brown is an Associate Research Fellow in the Worldwide Medicinal Chemistry group at Pfizer. He earned his B.S. in chemistry from Hope College in Holland, Michigan, and his Ph.D. in chemistry from the University of California, San Diego.

Bob Dugger is a Research Fellow in Chemical Research and Development at Pfizer. He earned his B.S. in chemistry from the University of Missouri, St. Louis, and his Ph.D. in organic chemistry from the University of California, Berkeley.

Frank Busch is a Research Advisor in Chemical Research and Development at Pfizer, where he has contributed to several projects including tofacitinib (XELJANZ®). He received his B.S. at Pennsylvania State University and his Ph.D. in organic chemistry at Massachusetts Institute of Technology.

Douglas Ball is a Research Fellow in Regulatory Strategy and Compliance at Pfizer and is the Nonclinical Drug Safety Team Lead for XELJANZ® (tofacitinib citrate). He obtained his B.S. and M.S. in biology from St. John’s University, Jamaica, NY.

William Brissette is formerly Senior Principal Scientist, Immunology Discovery Biology. Following retirement from Pfizer in 2007, he continued research on hematopoietic growth factor receptor signaling as a Visiting Fellow, Department of Molecular Biophysics and Biochemistry, Yale University. He earned his B.S. and M.S. from the University of Massachusetts.

Paul Changelian joined Pfizer in 1989 and was there until 2007. He is currently an independent consultant. He is a graduate of the University of Michigan. He received his Ph.D. in immunology from Harvard University and completed a postdoctoral fellowship in neurobiology at Washington University in St. Louis.

Not Pictured - Todd Blumenkopf and Michael Fisher

The American Chemical Society honors scientists at Pfizer whose innovation and commercialization of XELJANZ® (tofacitinib citrate), a revolutionary oral therapy for the treatment of rheumatoid arthritis. XELJANZ® is the first oral kinase inhibitor approved for a non-oncology indication.

Sally Gut-Ruggeri is an Associate Research Fellow in Chemical Research and Development at Pfizer. She earned her A.B. in chemistry from Cornell University, her Ph.D. in chemistry from the University of Wisconsin-Madison, and followed with an NIH-sponsored post-doctoral fellowship at Stanford University.

Elizabeth Kudlacz is currently a Director in Clinical Research and Development, Global Innovative Pharma Business Unit at Pfizer, Inc. She earned her B.S. in pharmacy and Ph.D. in pharmacology from Ohio State University.

Mark Flanagan is a graduate of New York University. He received his Ph.D. in organic chemistry from Colorado State University in 1995 and went on to study as an NIH postdoctoral fellow at the University of California, Berkeley before joining Pfizer, Inc. in 1997.

Rajappa Vaidyanathan, after 12 years at Pharmacia/Pfizer, he moved to Bristol-Myers Squibb where he is now a Director in Chemical Development. He obtained his B.Sc. from Loyola College, his M.Sc. from IIT, Madras, his Ph.D. from the University of California, Irvine, and completed a post-doctoral fellowship at Eli Lilly.

Eileen Elliott was formally Director of Immunology and is currently Executive Director in the External Research Solutions group at Pfizer. She earned her B.S. in biology from St. Bonaventure University, her Ph.D. in immunology from Albany Medical College of Union University, followed by a post-doctoral fellowship at Yale University.

Michael Munchhof, formerly a Senior Principal Scientist at Pfizer Inc., is currently an Independent Medicinal Chemistry Consultant working with several biopharma companies, providing drug design and due diligence expertise. He earned a Ph.D. in organic chemistry from the University of California, Berkeley and his B.A. from Indiana University Southeast.

Frank Urban is a former Senior Research Fellow with Process R&D at Pfizer in Groton. He retired in 2005. He earned his B. S. in organic chemistry at the Illinois Institute of Technology and his Ph.D. in organic chemistry from Pennsylvania State University.

Chakrapani Subramanyam is an Associate Research Fellow in Worldwide Medicinal Chemistry at Pfizer. He is a graduate of the University of Madras and received his Ph.D. in organic chemistry from Pennsylvania State University. He was a postdoctoral fellow at SUNY, Albany before joining Pfizer in 1996.

2014Aegerion/Bristol-Myers Squibb, Asahi Kasei Corporation, The Dow Chemical Company, Pfizer

2013DuPont, Merck, Pfizer, Vertex

2012Arkema, Merck, Novartis

2011AstraZeneca, DuPont

2010Merck, Pfizer

20093M, The Dow Chemical Company, Novartis

2008ExxonMobil Research and Engineering Company, Genentech, GlaxoSmithKline, Pfizer, Wyeth

2007Chevron Phillips Chemical Company, DuPont, ExxonMobil Research and Engineering Company, Genencor, Novartis Institutes for BioMedical Research, Pfizer, Tate & Lyle

2006ATMI, DuPont, Eli Lilly and Company, Merck, Rohm and Haas Company, Wyeth

2005Colgate-Palmolive Company, ExxonMobil Corporation, IBM, Johnson & Johnson Pharmaceutical Research and Development, Novartis Institutes for Biomedical Research

20043M, QLT, Schering-Plough Corporation, Wyeth Pharmaceuticals

2003 Abbott Laboratories, Merck, Pfizer, Wyeth Pharmaceuticals

2002 DSM, DuPont, Solutia

2000BASF Aktiengesellschaft, Bristol-Myers Squibb, Calgon Carbon Corp., The Dow Chemical Company, Energy Conversion Devices, Novartis Pharmaceuticals AG, Pfizer, PLIVA d.d., The Procter & Gamble Company, The R. W. Johnson Pharmaceutical Research Institute, Xerox

1999American Cyanamid Company, Bayer Corp., Dow AgroSciences, DuPont, Hercules, Inc., National Starch and Chemical Company, Pfizer, The Procter & Gamble Company

1998Ashland Chemical Company, Exxon Chemical/PARAMINS, Mobil Technology Company, Phillips Petroleum Texaco, UOP

19973M, AlliedSignal, DuPont, Eastman Kodak, IBM, Phillips Petroleum, Stepan, Union Camp

1996Air Products and Chemicals, Albemarle, Alliant Tech Systems, Eastman Kodak, General Magnaplate, Hamilton Standard, Inorganic Coatings, Lawrence Livermore National Laboratories, Morton International, NASA Langley Research Center, PCP, Systems & Process Engineering Corp., Thiokol Corp., TRW

Our Heroes of Chemistry have excelled in their work with some of the leading international corporations in their fields.

®

THE AMERICAN CHEMICAL SOCIETYFounded in 1876, ACS is the world’s largest scientific society dedicated to a single discipline. The Society’s members include chemists, chemical engineers, and other practitioners of the chemical sciences who work in industry, academia, government, consulting firms, and independently.

From its inception, ACS has been dedicated to providing the most accurate and comprehensive chemical information. Its mission includes encouraging in the broadest manner possible the advancement of the chemical enterprise and its practitioners, education, and public understanding of science. Its link to serving industry was reaffirmed in 1937, when ACS received its charter from the 75th Congress of the United States, and in 1952, when the Society organized Corporation Associates, an advisory group that now consists of more than 20 industrial companies and several governmental agencies and laboratories, which ensure that ACS provides valuable services to its industrial members and their companies.

Today, ACS plays a leadership role in educating and communicating with citizens, students, public leaders, and others about the importance of chemistry in developing new solutions, improving public health, protecting the environment, and contributing to the economy. The Society’s commitment to its members employed by industry continues with programs developed specifically for industrial chemical scientists, such as the Heroes of Chemistry program.